- Home
- PETZ vs BIVI Comparison
PETZ vs BIVI Comparison
Compare PETZ & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | BIVI |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | China | United States |
| Employees | 12 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 13.3M |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PETZ | BIVI |
|---|---|---|
| Price | $1.13 | $1.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.1K | ★ 229.4K |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $1.06 |
| 52 Week High | $1.83 | $8.84 |
Technical Indicators
Market Signals| Indicator | PETZ | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 47.62 |
| Support Level | $1.11 | $1.74 |
| Resistance Level | $1.23 | $2.17 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 13.01 | 32.27 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.